
This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda

0.25 to 1

To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria DESCRIPTION

Minocycline hydrochloride, USP, is a semisynthetic derivative of tetracycline. 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride. Its structural formula is



C23H27N3O7•HCI M.W. 493.94

Minocycline hydrochloride capsules USP for oral administration contain minocycline hydrochloride, USP equivalent to 50 mg, 75 mg, or 100 mg of minocycline. Inactive Ingredients

Inactive Ingredients Drug Product com starch and magnesium stearate. *Capsule Shell*: gelatin and titanium dioxide. In addition, the 100 mg capsule shells contain D&C Red #28, FD&C Blue #1, FD&C Red #40, and red ino xoide; the 75 mg capsule shells contain black iron oxide; and the 50 mg capsule shells contain D&C Red #33, FD&C Red #3, and FD&C Yellow #6. Printing Ink: black ino xoide, propylene glycol, D&C Yellow #10 Aluminum Lake, FD&C Blue #1 Aluminum Lake, FD&C Blue #2 Aluminum Lake, FD&C Red #40 Aluminum Lake and shellac. In addition, the 50 mg and 100 mg ink contains strong ammonia solution.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY Following a single dose of two minocycline hydrochloride capsules, 100 mg administered to 18 normal fasting adult volunteers, maximum serum concentrations were attained in 1 to 4 hours (average 2.1 hours) and ranged from 2.1 to 5.1 mcg/mL (average 3.5 mcg/mL). The serum half-life in the normal volunteers ranged from 11.1 to 22.1 hours (average 15.5 hours).

11.1 to 22.1 hour of versage ros Jonson.
When minocycline hydrochloride capsules were given concomitantly with a high-fat meal, which included dairy products, the extent of absorption of minocycline hydrochloride capsules was unchanged compared to dosing under fasting conditions. The mean T_{max} was delayed by one hour when administered with food, compared to dosing under fasting conditions. Minocycline hydrochloride capsules may be administered with or without food.

In previous studies with other minocycline dosage forms, the minocycline serum half-life ranged from 11 to 16 hours in 7 patients with hepatic dysfunction, and from 18 to 69 hours in 5 patients with renal dysfunction. The urinary and fecal recovery of minocycline when administered to 12 normal volunteers was one-half to one-third that of other tetracyclines.

Rev. Q 9/2012

MINOCYCLINE HYDROCHLORIDE Capsules USP

3165 3167

 ${
m R}$ only

Microbiology The tetracyclines are primarily bacteriostatic and are thought to exert their antimicrobial effect by the inhibition of protein synthesis. The tetracyclines, including the inhibition of protein synthesis. The tetracyclines, including ninocycline, have a similar antimicrobial spectrum of activity against a wide range of gram-positive and gram-negative organisms. Cross-resistance of these organisms to tetracycline is common

Minocycline has been shown to be active against most strains of the following microorganisms, both *in vitro* and in clinical infections as described in the INDICATIONS AND USAGE section:

GRAM-POSITIVE BACTERIA

Because many strains of the following gram-positive microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are especially recommended. Tetracycline antibiotics should not be used for streptococcal diseases unless the organism has been demonstrated to be susceptible. Tetracyclines are not the drug of choice in the treatment of any type of staphylococcal infection.

Bacillus anthracis ¹ Listeria monocytogenes ¹ Staphylococcus aureus Staphylococcus aureus GRAM-NEGATIVE BACTERIA Bartonella bacilliformis Brucella species Calymnatobacterium granulomatis Campylobacter fetus Francisella tularensis Haemophilus ducreyi Vibrio cholerae Yersinia pastis
Because many strains of the following groups of gram-negative microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility tests are especially recommended.
Acintebacter species Enterobacter aerogenes Escherichia coli Haemophilus influenzae Klabsiella species Neisseria gonorrhoea ¹ Neisseria gonorrhoea ¹ Neisseria gonorrhoea ¹ Shigella species
"OTHER" MICROORGANISMS Actinomyces species ¹ Borrelia recurrentis Chiamydia trachomatis Clostridium species ¹ Entamoeba species Fusobacterium nucleatum subspecies fusiforme ¹ Mycobacterium nucleatum subspecies fusiforme ¹ Mycobacterium antinum Mycopiasma pneumoniae Propionibacterium acnes

Rickettsiae Treponema pallidum subspecies pa Treponema pallidum subspecies p

Ureaplasma urealyticum

¹ When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections caused by the cited microorganisms.

Suscentibility Tests

Susceptibility testing should be performed with tetracycline since it predicts susceptibility to minocycline. However, certain organisms (e.g., some staphylococci, and Acinetobacter species) may be more susceptible to minocycline and doxycycline than to tetracycline.

Dilution techniques Quantitative methods are used to determine antimicrobial minimal inhibitory Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MIGs). These MIGs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MIGs should be determined using a standardized procedure. Standardized procedures are based on a dilution method (Ref1, Ref3) (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of tetracycline powder. The MIC values should be interpreted according to the following criteria:

For testing aerobic gram-negative microorganisms (Enterobacteriaceae), Acinetobacter spp., and Staphylococcus aureus:

MIC (mcg/mL)	Interpretation
≤ 4	Susceptible (S)
8	Intermediate (I)
≥ 16	Resistant (R)
For testing Haemophilus influe	enzae ² and Streptococcus pneumoniae ³ :
MIC (mcg/mL)	Interpretation
≤ 2	Susceptible (S)
4	Intermediate (I)

Resistant (R) These interpretative standards are applicable only to broth microdilution susceptibility sting with *Haemophilus influenzae* using *Haemophilus* Test Medium. esting with

³ These interpretative standards are applicable only to broth microdilution susceptibility testing using cation-adjusted Mueller-Hinton broth with 2 to 5% lysed horse blood.

For testing Neisseria gonorrhoeae4 :	
MIC (mcg/mL)	Interpretation

	MIC (mcg/mL)	Interpretation
	≤ 0.25	Susceptible (S)
	0.5 to 1	Intermediate (I)
	≥ 2	Resistant (R)
į	4 These interpretative standards are ap	alicable only to agar dilution suscentibility

⁴ These interpretative standards are applicable only to agar dill testing using GC agar base and 1% defined growth supplements.

A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of "intermediate" indicates that the result should be considered achievable. A report of "Intermediate" indicates that the result should be considered equivocal and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.

Quality Control Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard tetracycline powder should provide the following MIC values:

orandara torradyonno portadi onotila provido tito tonoring into valado.		
	Microorganism	MIC Range (mcg/mL)
Es	scherichia coli ATCC 25922	0.5 to 2
S	taphylococcus aureus ATCC 29213	0.12 to 1
H	aemophilus influenzae ATCC 49247	4 to 32
S	trentococcus nneumoniae ATCC 49619	0.06 to 0.5

Neisseria gonorrhoeae ATCC 49226

Diffusion techniques Quantitative methods that require measurement of zone diameters also provi reproducible estimates of the susceptibility of bacteria to antimicrobial compound One such standardized procedure BE/2. Bel3 requires the use of standardized the successful uses name disks impregnated w inoculum concentrations. This procedure uses paper disks impregnated with 30 mcg tetracycline (class disk) or 30 mcg minocycline to test the susceptibility of microorganisms to minocycline.

Reports from the laboratory providing results of the standard single-disk susceptibility test with a 30 mcg tetracycline or minocycline disk should be interpreted according to the following criteria:

For testing aerobic Enterobacteriaceae and Acinetobacter spp.

Zone Diameter (mm)	Interpretation	MIC (mcg/mL)
≥ 16	Susceptible (S)	≤ 4
13 to 15	Intermediate (I)	-
≤ 12	Resistant (R)	≥ 16

Mueller-Hinton agar and 30 mcg minocycline disk. For testing Staphylococcus aureus

Zone Diameter (mm)	Interpretation	MIC (mcg/mL)
≥ 19	Susceptible (S)	≤ 4
15 to 18	Intermediate (I)	
≤ 14	Resistant (R)	≥ 16
These zone diameter standards are applicable only to susceptibility testing using		

Mueller-Hinton agar and a 30 mcg minocycline disk.

FUL	esting naemophilus innue	nzae°.	
	Zone Diameter (mm)	Interpretation	MIC (mcg/mL)
	≥ 29	Susceptible (S)	≤ 2
	26 to 28	Intermediate (I)	-
	≤ 25	Resistant (R)	≥ 8
5 ти	and some diameter stand	arda ara applicable aplu	to ourocontibility tooti

These zone diameter standards are applicable only to susceptibility testing with *Haemophilus influenzae* using *Haemophilus* Test Medium and a 30 mcg tetracycline disk. For testing Neisseria gonorrhoeae6

MIC (mcg/mL) Zone Diameter (mm) Interpretatio Susceptible (S) ≤ 0.25 31 to 3 Intern rediate

≤ 30	Resistant (R)	≥ Z	
⁶ These interpretative standar using GC agar and 1% growt			
For testing Streptococcus pneun	noniae ⁷ :		

Zone Diameter (mm)	Interpretation	MIC (mcg/mL)
≥ 23	Susceptible (S)	≤ 2
19 to 22	Intermediate (I)	-
≤ 18	Resistant (R)	≥ 8

⁷ These interpretative standards are applicable only to disk diffusion testing using Mueller-Hinton agar adjusted with 5% sheep blood and a 30 mcg tetracvcline disk.

Interpretation should be as stated above for results using dilution techniq Interpretation involves correlation of the diameter obtained in the disk test with MIC for tetracycline.

As with standardized dilution techniques, diffusion methods require the use of The mini variable index is a match to be applied on the set of the

Microorganism	Zone Diameter Range (mm)	
	Tetracycline	Minocycline
Escherichia coli ATCC 25922	18 to 25	19 to 25
Staphylococcus aureus ATCC 25923	24 to 30	25 to 30
Haemophilus influenzae ATCC 49247	14 to 22	-
Neisseria gonorrhoeae ATCC 49226	30 to 42	-
Streptococcus pneumoniae ATCC 49619	27 to 31	-

Importantions and obsect innocycline hydrochloride capsules USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, tybus fever and the tybus group, Q fever, ricketfisalpox and tick fevers caused by vicketfisae. Respiratory tract infections caused by Vichaldsmam pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Omithosis) due to Chlamydia trachomatis. Psittacosis (Omithosis) due to Chlamydia trachomatis. Psittacosis (Jonithosis) due to Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealylicium or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Chlamydia Loreyj. Plague due to Yrsinia pestis. Tuiaremia due to Francisella tularensis. Cholera caused by Vibiar voltares. Minocycline hydrochloride cansules USP are indicated in the treatment of the

Iularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin) Bartonellosis due to Bartonella baciliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis.

Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug:

Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species.

Respiratory tract infections caused by *Haemophilus influenzae*. Respiratory tract and urinary tract infections caused by *Klebsiella* species.

Respiratory rate and unitary fract mections caused by *Neuseina* species. Minocycline hydrocholride capsules USP are indicated for the treatment of inflections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract indections caused by *Staptococcus pneumoniae*. Skin and skin structure infections caused by *Staptylococcus aureus*. (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.)

When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the

HYDROCHLORIDE CAPSULES USP

your medical condition or treatment.

Read the Patient Information that comes with minocycline hydrochloride capsules USP before you or

a family member starts taking them and each time you

get a refill. There may be new information. This leaflet

does not take the place of talking to your doctor about

What are minocycline hydrochloride capsules USP?

Minocycline hydrochloride capsules USP are a

tetracycline-class antibiotic medicine. Minocycline

hydrochloride capsules USP are used to treat

certain infections caused by bacteria. These include

infections of the skin, respiratory tract, urinary tract, some sexually transmitted diseases, and others. Minocycline hydrochloride capsules USP may be

Sometimes, other germs, called viruses cause

infections. The common cold is a virus. Minocycline

hydrochloride capsules USP, like other antibiotics, do

Who should not use minocycline hydrochloride

Do not take minocycline hydrochloride capsules USP if you are allergic to minocycline or other

Ask your doctor or pharmacist for a list of these

medications if you are not sure. See the end of this

leaflet for a complete list of ingredients in minocycline

Minocycline hydrochloride capsules USP are not

recommended for pregnant women or children up

1. Minocycline hydrochloride capsules USP may

Minocycline hydrochloride capsules USP may

permanently turn a baby's or child's teeth

yellow-gray-brown during tooth development.

Tooth development happens in the last half of

What should I tell my doctor before starting

Tell your doctor about all of your medical conditions,

• are pregnant or planning to become pregnant. Minocycline hydrochloride capsules USP may harm your unborn baby. Stop taking minocycline

hydrochloride capsules USP and call your doctor

if you become pregnant while taking them.

• are breast feeding. Minocycline passes into

Tell your doctor about all the medicines you are

taking including prescription and non prescription medications, vitamins, and herbal supplements,

Minocycline hydrochloride capsules USP and other

medicines may interact. Especially tell your doctor

• birth control pills. Minocycline hydrochloride

• a blood thinner medicine. The dose of your blood

• a penicillin antibiotic medicine. Minocycline

An acne medicine called isotretinoin (Accutane,

 Antacids that contain aluminum, calcium, or magnesium, or iron-containing products.

Know the medicines you take, keep a list of them to

show your doctor and pharmacist each time you get

How should I take minocycline hydrochloride

• Take minocycline hydrochloride capsules USP

· Decrease the effectiveness of the treatment

hydrochloride capsules USP may:

exactly as your doctor tells you to take them.

Skipping doses or not taking all your minocycline

• Increase the chance that bacteria will develop resistance to minocycline hydrochloride

Take minocycline hydrochloride capsules USP

with a full glass of liquid. Taking minocycline hydrochloride capsules USP with enough liquid

may lower your chance of getting irritation or ulcers in your esophagus. Your esophagus is the

tube that connects your mouth to your stomach.

Migraine medicines called ergot alkaloids

hydrochloride capsules USP and penicillins should

thinner may have to be lowered.

Amnesteem, Claravis, Sotret)

capsules USP may make your birth control pills

your milk and may harm your baby. You should

decide whether to use minocycline hydrochloride capsules USP or breastfeed, but not both.

pregnancy and birth to age 8 years.

minocycline hydrochloride capsules USP?

• have liver or kidney problems

used along with other treatments for severe acne.

 $m R\!\!\prime$ only

not treat viruses

capsules USP?

tetracycline antibiotics.

hydrochloride capsules USP.

harm an unborn baby

to 8 years old because:

including if you:

if you take:

less effective

a new medicine.

capsules USP?

capsules USP

not be used together.

2.

Uncomplicated uretinitis in men que to Nersearia gono treatment of other gonococcal infections. Infections in women caused by Neisseria gonorrhoeae. Syphilis caused by Tregonema pallidum subspecies pallidum Yaws caused by Tregonema pallidum subspecies parlenue. Listeriosis due to Listeria monocytogenes. Anthrax due to Bacillus anthracis.

Anthrax due to Bacillus anthracis. Vincent's infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species.

In acute intestinal amebiasis, minocycline may be a useful adjunct to amebicides

In severe acne, minocycline may be useful adjunctive therapy.

Oral minocycline is indicated in the treatment of asymptomatic carriers of Neiss meninaitidis to eliminate meningococci from the nasopharynx. In order to presmeningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal the userulines of intrologitine in the readment of a symplomatar meningbotca carriers, diagnostic laboratory procedures, including serotyphing and susceptibility testing, should be performed to establish the carrier state and the correct treatment its recommended that the prophylacitic use of minocycline be reserved for situation-in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection

Although no controlled clinical efficacy studies have been conducted, limited clinic data show that oral minocycline hydrochloride has been used successfully in th treatment of infections caused by *Mycobacterium marinum*.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules USP and other antibacterial drugs, minocycline hydrochloride capsules USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility catterias, mark contribute to the semiciric selection of therapy. susceptibility patterns may contribute to the empiric selection of therapy. CONTRAINDICATIONS

This drug is contraindicated in persons who have shown hypersensitivity to any of the tetracyclines or to any of the components of the product formulation. WARNINGS

WARNINGS MINOCYCLINE HYDROCHLORIDE CAPSULES, LIKE OTHER TETRACYCLINE-CLASS ANTIBIOTICS, CAN CAUSE FETAL HARM WHEN ADMINISTERED TO A PREGNANT WOMAN. IF ANY TETRACYCLINE IS USED DURING PREGNANCY OR IF THE PATIENT BECOMES PREGNANT WHILE TAKING THESE ORUGS, THE PATIENT SHOULD BE APPRISED OF THE POTENTIAL HAZARD TO THE FETH OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY, AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLOMETORY DETHE TETRA YEARD MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY-BROWN).

This adverse reaction is more common during long-term use of the drug but has been observed following repeated short-term courses. Enamel hypoplasia has also This adverse features index common during tongent mass of the origination as been observed following repeated short-term courses. Enamel hypopiasia has also been reported. TETRACYCLINE ORUGS, THEREFORE, SHOULD NOT BE USED DURING TOOTH DEVELOPMENT UNLESS OTHER DRUGS ARE NOT LIKELY TO BE EFFECTIVE OR ARE CONTRAINDICATED.

All tetracyclines form a stable calcium complex in any bone-forming tissue. A decrease in the fibula growth rate has been observed in premature human infants uservesse in the fibula growth rate that been observed in premature human infants given oral tetracycline in doses of 25 mg/kg every six hours. This reaction was shown to be reversible when the drug was discontinued. Regulte of angle terrefacement

Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity has been noted in animals treated early in pregnancy.

Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) incl have been reported with minocycline use. If this syndrome is reco should be discontinued immediately.

The anti-anabolic action of the tetracyclines may cause an increase in BUN. While this is not a problem in those with normal renal function, in patients with significantly impaired function, higher serum levels of tetracycline may lead to azotenia, hyperphosphatemia, and acidosis. Under such conditions, monitoring of creatinine and BUN is recommended, and the total daily dosage should not exceed 200 mg in 24 hours (see DOSAGE AND ADMINISTRATION). If renal impairment exists, even usual oral or parenteral doses may lead to systemic accumulation of the drug and possible liver toxicity.

possible liver toxicity. Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. This has been reported with minocycline. Central nervous system side effects including light-headedness, dizziness, or vertigo have been reported with minocycline therapy. Patients who experience these symptoms should be cautioned about driving vehicles or using hazardous machinery while on minocycline therapy. These symptoms may disappear during therapy and usually disappear rapidly when the drug is discontinued.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly

antibacterial agents, including minocycline hydrochorde, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*. C. difficile produces toxins A and B which contribute to the development of CDAD

Commer produces to this A and B wind to influence on the development of CADM Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhes following antibiotic use. Careful medical history is necessary since CDAD has beer reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.

PRECAUTIONS

General As with other antibiotic preparations, use of this drug may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, the antibiotic should be discontinued and appropriate therapy instituted.

Pseudotumor cerebri (benion intracranial hypertension) in adults has been associated seculation of electrony interaction of the second matching of the second and the second associated with the use of tetracyclines. The usual cilicitical manifestations are headache and blurred vision. Bulging fontanels have been associated with the use of tetracyclines infrants. While both of these conditions and related symptoms usually resolve after discontinuation of the tetracycline, the possibility for permanent sequelae exists. Hepatotoxicity has been reported with minocycline; therefore, minocycline should be used with caution in patients with hepatic dysfunction and in conjunction with other hepatotoxic drugs.

Content repartitudes utgs.
Incision and drainage or other surgical procedures should be performed in conjunction with antibiotic therapy when indicated.
Prescribing minocycline hydrochloride capsules in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Information for Patients

Laboratory Tests

for at least four months.

Information for Patients Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible

Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema. This reaction has been reported with use of minocycline.

Patients who experience central nervous system symptoms should be cautioned about driving vehicles or using hazardous machinery while on minocycline therapy about driving veh (see **WARNINGS**)

Concurrent use of tetracycline with oral contraceptives may render oral contraceptives less effective (see **Drug Interactions**).

Patients should be counseled that antibacterial drugs including minocycline hydrochloride capsules should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When minocycline hydrochloride capsules are prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by minocycline hydrochloride capsules or other antibacterial drugs in the future Unused supplies of tetracycline antibiotics should be discarded by the expiration date

In venereal disease when coexistent syphilis is suspected, a dark-field examination should be done before treatment is started and the blood serology repeated monthly

Periodic laboratory evaluations of organ systems, including hematopoietic, renal and hepatic, should be performed.

- Minocycline hydrochloride capsules USP may be taken with or without food. If you forget to take minocycline hydrochloride capsules USP, take them as soon as you remember.
- -If you take too many minocycline hydrochloride capsules USP, call your doctor or poison control center right away

What are the possible side effects of minocycline hydrochloride capsules USP?

Minocycline hydrochloride capsules USP may cause serious side effects. Stop minocycline hydrochloride capsules USP and call your doctor if you have:

- watery diarrhea
- bloody stools
- stomach cramps
- unusual headaches
- blurred vision
- fever
- rash
- ioint pain
- · feeling very tired

Minocycline hydrochloride capsules USP may also cause:

- central nervous system effects. Symptoms include light-headedness, dizziness, and a spinning feeling (vertigo). You should not drive or operate machines if you have these symptoms.
- sun sensitivity (photosensitivity). You may get a worse sunburn with minocycline hydrochloride capsules USP. Avoid sun exposure and the use of sunlamps or tanning beds. Protect your skin while out in the sunlight. Stop minocycline hydrochloride capsules USP and call your doctor if your skin turns red.

These are not all the side effects with minocycline hydrochloride capsules USP. Ask your doctor or pharmacist for more information.

How should I store minocycline hydrochloride capsules USP?

- · -Store minocycline hydrochloride capsules USP at room temperature and away from excess heat and moisture
- -Throw away any minocycline hydrochloride capsules USP that are outdated or no longer needed.

• Keep minocycline hydrochloride capsules USP and all medicines out of the reach of children. General advice about minocycline hydrochloride

capsules USP Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use minocycline hydrochloride capsules USP

for a condition for which they were not prescribed. Do not give minocycline hydrochloride capsules USP to other people, even if they have the same symptoms you have. It may harm them.

This Patient Information leaflet summarizes the most important information about minocycline hydrochloride capsules USP. If you would like more information, talk with your doctor.

Your doctor or pharmacist can give you information about minocycline hydrochloride capsules USP that is written for health care professionals. For more information, you can also call Teva Pharmaceuticals USA at 1-888-838-2872, MEDICAL AFFAIRS.

What are the ingredients in minocycline hydrochloride capsules USP?

Active ingredient: minocycline hydrochloride, USP, 50 mg, 75 mg, and 100 mg

Inactive ingredients: Drug Product: corn starch and magnesium stearate. Capsule Shell: gelatin and titanium dioxide. In addition, the 100 mg capsule shells contain D&C Red #28, FD&C Blue #1, FD&C Red #40, and red iron oxide; the 75 mg capsule shells contain black iron oxide; and the 50 mg capsule shells contain D&C Red #33. FD&C Red #3. and FD&C Yellow #6. Printing Ink: black iron oxide, propylene glycol, D&C Yellow #10 Aluminum Lake, FD&C Blue #1 Aluminum Lake, FD&C Blue #2 Aluminum Lake, FD&C Red #40 Aluminum Lake and shellac. In addition, the 50 mg and 100 mg ink contains strong ammonia solution.

TEVA PHARMACEUTICALS USA Sellersville, PA 18960

Reference ID: 3238780

Rev. B 9/2012

For current labeling information, please visit https://www.fda.gov/drugsatfda **Drug Interactions** DOSAGE AND ADMINISTRATION

Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline-class drugs in conjunction with penicillin. Absorption of tetracyclines is impaired by antacids containing aluminum, calcium, or magnesium, and iron-containing preparations.

The concurrent use of tetracycline and methoxyflurane has been reported to result

in fatal renal toxicity Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.

Administration of isotretinoin should be avoided shortly before, during, and shortly after minocycline therapy. Each drug alone has been associated with pseudotumor cerebri (see **PRECAUTIONS**).

Increased risk of ergotism when ergot alkaloids or their derivatives are given with etracyclines

Drug/Laboratory Test Interactions False elevations of urinary catecholamine levels may occur due to interference with the fluorescence test. Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis, Mutagenesis, impairment of refruitiv Dietary administration of minocycline in long-term tumorigenicity studies in rats resulted in evidence of thyroid tumor production. Minocycline has also been found to produce thyroid hyperplasia in rats and dogs. In addition, there has been evidence of oncogenic addivity in rats in studies with a related antibiotic, oxytetracycline (i.e., adrenal and pituitary tumors). Likewise, although mutagenicity studies of minocycline have not been conducted, positive results in *in vitro* mammalian cell assays (i.e., mouse) tymphoma and Chinese hamster lung cells) have been reported for crited entibilistic (determine hydrodethydrauterstream).

assays (i.e., industry implorted and connect and constrained a Pregnancy Teratogenic Effects

Pregnancy category D (See WARNINGS.)

(See WARNINGS.) All pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. There are no adequate and well-controlled studies on the use of minocycline in pregnant women. Minocycline, like other tetracycline-class antibiotics, crosses the placenta and may cause fetal harm when administered to a pregnant woman. Rare spontaneous reports of congenital anomalies including limb reduction have been reported in postmarketing experience. Only limited information is available regarding these reports; therefore, no conclusion on causal association can be established. If minocycline is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

Nonteratogenic Effects (See WARNINGS.)

Labor and Delivery

The effect of tetracyclines on labor and delivery is unknown. Nursing Mothers

excreted in human milk. Because of the potential for se in nursing infants from the tetracyclines, a decision shou serious made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother (see WARNINGS).

Pediatric Use Minncvcline is not recommended for the use in children below 8 years of age unless the expected benefits of therapy outweigh the risks (see WARNINGS Geriatric Use

Genance Use Clinical studies of oral minocycline did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, does selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see WARNINGS, DOSAGE AND ADMINISTRATION). Minocycline capsules USP (50 mg, 75 mg, and 100 mg) do not contain sodium

ADVERSE REACTIONS Due to oral minocycline's virtually complete absorption, side effects to the lower

bowel, particularly diarrhea, have been infrequent. The following adverse reactions have been observed in patients receiving tetracyclines.

Rody as a Whole: Fever and discoloration of secretions

Body as white: very and incontino to solventiate, Gastrointestinal: Anorexia, nausea, vomiting, diarrhea, dyspepsia, stomattils, glossitis, dysphagia, enamel hypoplasia, enterocolitis, pseudomembranous colitis, pancreatitis, inflammatory lesions (with monilial overgrowth) in the oral and anogenital regions. Instances of esophagitis and esophageal ulcerations have been reported in patients taking the tetracycline-class antibiotics in capsule and tablet form. Most of these patients took the medication immediately before going to bed (see DOSAGE AND ADMINISTRATION).

Genitourinary: Vulvovaginitis.

Hepatic Toxicity: Hyperbilirubinemia, hepatic cholestasis, increases in liver enzymes fatal hepatic failure, and jaundice. Hepatitis, including autoimmune hepatitis, and liver failure have been reported (see **PRECAUTIONS**).

Skin: Alopecia, erythema nodosum, hyperpigmentation of nails, pruritus, epidermal necrolysis, and vasculitis. Maculopapular and erythematous r eproerman necrolysis, and vasculitis. Maculopapular and erymematous rashes. Extollative demantitis has been reported. Fixed drug eruptions have been reported. Lesions occurring on the glans penis have caused balanitis. Erythema multiforme and Stevens-Johnson syndrome have been reported. Photosensitivity is discussed above (see **WARINGS**). Pigmentation of the skin and mucous membranes has been reported.

Respiratory: Cough, dyspnea, bronchospasm, exacerbation of asthma, and pneumonitis

Renal Toxicity: Interstitial nephritis. Elevations in BUN have been reported and are apparently dose related (see **WARNINGS**). Reversible acute renal failure has been reported.

Musculoskeletal: Arthralgia, arthritis, bone discoloration, myalgia, joint stiffness, and joint swelling.

Hypersensitivity Reactions: Urticaria, angioneurotic edema, polyarthralgia, anaphylaxiSnaphylactoid reaction (including shock and fatalities), anaphylactoid purpura, myocarditis, pericarditis, exacerbation of systemic lupus erythematosus and pulmonary infiltrates with eosinophilia have been reported. A transient lupus-like syndrome and serum sickness-like reactions also have been reported.

Blood: Agranulocytosis, hemolytic anemia, thrombocytopenia, leukopenia, neutropenia, pancytopenia, and eosinophilia have been reported.

Central Nervous System: Convulsions, dizziness, hypesthesia, paresthesia, sedation and vertigo. Bulging fontanels in infants and benign intracranial hypertensior (pseudotumor cerebri) in adults have been reported (see **PRECAUTIONS, General**) (pseudotumor cerebri) in addits i Headache has also been reported. Other: Thyroid cancer has been reported in the post-marketing setting in association

with minocycline products. When minocycline therapy is given over prolonged periods, monitoring for signs of thyroid cancer should be considered. When given over prolonged periods, tetracyclines have been reported to produce brown-black increscopic discoloration of the thyroid gland. Cases of abnormal thyroid function have been reported

Tooth discoloration in children less than 8 years of age (see WARNINGS) and also, in adults has been reported. Oral cavity discoloration (including tongue, lip, and gum) have been reported

Tinnitus and decreased hearing have been reported in patients on minocycline

The following syndromes have been reported. In some cases involving these syndromes, death has been reported. As with other serious adverse reactions, if any of these syndromes are recognized, the drug should be discontinued immediately:

Hypersensitivity syndrome consisting of cutaneous reaction (such as rash or exoliative dermatitis), eosinophila, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis. Fever and lymphadenopathy may be present.

Lupus-like syndrome consisting of positive antinuclear antibody; arthralgia, arthritis joint stiffness, or joint swelling; and one or more of the following: fever, myalgia hepatitis, rash, and vasculitis.

Serum sickness-like syndrome consisting of fever; urticaria or rash; and arthralgia, arthritis, joint stiffness, or joint swelling. Eosinophilia may be present. OVERDOSAGE

adverse events more commonly seen in overdose are dizziness, nausea. and vomiting

No specific antidote for minocycline is known

In case of overdosage, discontinue medication, treat symptomatically, and institute supportive measures. Minocycline is not removed in significant quantities by hemodialysis or peritoneal dialysis.

THE USUAL DOCAGE AND FROUENCY OF ADMINISTRATION OF MINOCYCLINE DIFFERS FROM THAT OF THE OTHER TETRACYCLINES. EXCEEDING THE RECOMMENDED DOSAGE MAY RESULT IN AN INCREASED INCIDENCE OF SIDE EFFECTS. pharmacist each time you get a new medi How should I take minocycline hydrochloride capsules USP? Take minocycline hydrochloride capsules USP exactly as your doctor tells you to take them. Skipping doses or not taking all your minocycline hydrochloride capsules USP may. Minocycline hydrochloride capsules USP may be taken with or without food

now the medicines you take, keep a list of them to show your doctor and

Increase the chance that bacteria will develop resistance to minocycline hydrochloride capsules USP

Take minocycline hydrochloride capsules USP with a full glass of liquid. Taking minocycline hydrochloride capsules USP with enough liquid may lower your chance of getting irritation or ulcers in your esophagus. Your esophagus is the tube that connects your mouth to your stomach.

Minocycline hydrochloride capsules USP may be taken with or without food If you forget to take minocycline hydrochloride capsules USP, take them as soon as you remember.

If you take too many minocycline hydrochloride capsules USP, call your doctor or poison control center right away.

What are the possible side effects of minocycline hydrochloride capsules USP?

Minocycline hydrochloride capsules USP may cause serious side effects. Stop minocycline hydrochloride capsules USP and call your doctor if you have:

central nervous system effects. Symptoms include light-headedness, dizziness, and a spinning feeling (vertigo). You should not drive or operate machines if you

• sun sensitivity (photosensitivity). You may get a worse sunburn with minocycline hydrochloride capsules USP. Avoid sun exposure and the use of sunlamps or tanning beds. Protect your skin while out in the sunlight. Stop minocycline hydrochloride capsules USP and call your doctor if your skin

These are not all the side effects with minocycline hydrochloride capsules USP. Ask your doctor or pharmacist for more information. How should I store minocycline hydrochloride capsules USP?

-Store minocycline hydrochloride capsules USP at room temperature and away from excess heat and moisture.

· -Throw away any minocycline hydrochloride capsules USP that are outdated

Keep minocycline hydrochloride capsules USP and all medicines out of the reach of children

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use minocycline hydrochloride capsules USP for a condition for which they were not prescribed. Do not give minocycline hydrochloride capsules USP to other people, even if they have the same symptoms you have. It

This Patient Information leaflet summarizes the most important information about minocycline hydrochloride capsules USP. If you would like more information, talk with your doctor.

Your doctor or pharmacist can give you information about minocycline hydrochloride capsules USP that is written for health care professionals. For more information, you can also call Teva Pharmaceuticals USA at 1-888-838-2872, MEDICAL AFFAIRS.

Active ingredient: minocycline hydrochloride, USP, 50 mg, 75 mg, and 100 mg

Retrie imperiation: Instructionate, USP, and magnesistic activity of the second sec

TEVA PHARMACEUTICALS USA

Rev. B 9/2012

What are the ingredients in minocycline hydrochloride capsules USP?

General advice about minocycline hydrochloride capsules USP

· Decrease the effectiveness of the treatment

watery diarrhea

unusual headaches

· bloody stools stomach cramps

blurred visior

· feeling very tired

have these symptoms.

or no longer needed.

Minocycline hydrochloride capsules USP may also cause

 fever · rash

joint pain

turns red.

may harm them

Rev. Q 9/2012

(see CLINICAL PHARMACOLOGY) Ingestion of adequate amounts of fluids along with capsule and tablet forms of drugs in the tetracycline-class is recommended to reduce the risk of esophageal irritation and ulceration. The capsules should be swallowed whole.

For Pediatric Patients Above 8 Years of Age Usual pediatric dose: 4 mg/kg initially followed by 2 mg/kg every 12 hours, not to exceed the usual adult dose.

Adults

This label may not be the latest approved by FDA.

The usual dosage of minocycline hydrochloride capsules USP is 200 mg initially followed by 100 mg every 12 hours. Alternatively, if more frequent doses are preferred, two or four 50 mg capsules may be given initially followed by one 50 mg capsule 4 times daily.

Uncomplicated gonococcal infections other than urethritis and anorectal infections in men: 200 mg initially, followed by 100 mg every 12 hours for a minimum of 4 days, with post-therapy cultures within 2 to 3 days.

In the treatment of uncomplicated gonococcal urethritis in men, 100 mg every 12 hours for 5 days is recommended.

For the treatment of syphilis, the usual dosage of minocycline hydrochloride capsules USP should be administered over a period of 10 to 15 days. Close follow-up, including laboratory tests, is recommended. In the treatment of meningococcal carrier state, the recommended dosage is 100 mg

every 12 hours for 5 days

Mycobacterium marinum infections: Although optimal doses have not been established, 100 mg every 12 hours for 6 to 8 weeks have been used successfully in a limited number of cases.

Uncomplicated urethral, endocervical, or rectal infection in adults caused by Chlamydia trachomatis or Ureaplasma urealyticum: 100 mg orally, every 12 hours or at least 7 days.

Ingestion of adequate amounts of fluids along with capsule and tablet forms of drugs in the tetracycline-class is recommended to reduce the risk of esophageal irritation and ulceration.

Inflation and user alon. The pharmacokinetics of minocycline in patients with renal impairment (CL_{CR} <80mL/min) have not been fully characterized. Current data are insufficient to determine if a dosage adjustment is warranted. The total daily dosage should not exceed 200 mg in 24 hours. However, due to the anti-anabolic effect of tetracyclines, BUN and creatinine should be monitored (see **WARNINGS**).

HOW SUPPLIED

HOW SUPPLIED Minocycline hydrochloride capsules USP are supplied as capsules containing minocycline hydrochloride, USP equivalent to 50 mg, 75 mg, and 100 mg minocycline: Capsules containing minocycline hydrochloride, USP equivalent to 50 mg minocycline. The 50 mg capsule is supplied with a pink body and cap and is imprinted "TEVA" on the cap and "3165" on the body, in bottles of 100.

Capsules containing minocycline hydrochloride, USP equivalent to 75 mg minocycline The 75 mg capsule is supplied with a light gray opaque body and white opaque cap and is imprinted "TEVA" on the cap and "7300" on the body, in bottles of 100.

Capsules containing minocycline hydrochloride, USP equivalent to 100 minocycline. The 100 mg capsule is supplied with a pink body and maroon cap is imprinted "TEVA" on the cap and "3167" on the body, in bottles of 50.

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature.] Protect from light, moisture and excessive heat

Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required)

KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

KEEP THIS AND ALL MEDICATIONS UDT OF THE HEACH OF CHILDHEN. ANIMAL PHARMACOLOGY AND TOXICOLOGY Minocycline hydrochloride has been observed to cause a dark discoloration of the thyroid in experimental animals (rats, minipigs, dogs, and monkeys). In the rat, chronic treatment with minocycline hydrochloride has resulted in goiter accompanied by elevated radioactive iodime uptake and evidence of thyroid tumor production. Minocycline hydrochloride has been found to produce thyroid hyperplasia in rats and dogs.

R only

capsules USE

REFERENCES Ref1. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard-Ninth Edition; Document M07-A9, Vol. 32, No. 2, CLSI, Wayne, PA, January, 2012

Ref2. Clinical and Laboratory Standards Institute. Performance Sta Antimicrobial Disk Susceptibility Tests; Approved Standard-Eleven Document M02-A11, Vol. 32, No. 1, CLSI, Wayne, PA, January, 2012

Ref3. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Second Informational Supplement. Document M100-S22, Vol. 32, No. 3, CLSI, Wayne, PA, January, 2012

This product's label may have been updated. For current package insert and further product information, please call our toll-free number: 1-888-838-2872, MEDICAL AFFAIRS. TEVA PHARMACEUTICALS USA Sellersville, PA 18960

PATIENT INFORMATION ABOUT MINOCYCLINE HYDROCHLORIDE CAPSULES USP

Read the Patient Information that comes with minocycline hydrochloride capsules USF

before you or a family member starts taking them and each time you get a refill. There

may be new information. This leaflet does not take the place of talking to your doctor about your medical condition or treatment.

What are initiocycline hydrochloride capsules USP are a tetracycline-class antibiotic medicine. Minocycline hydrochloride capsules USP are used to treat certain infections caused by bacteria. These include infections of the skin, respiratory tract, urinary tract, some sexually transmitted diseases, and others. Minocycline hydrochloride capsules USP may be used along with other treatments for severe acne.

Sometimes, other germs, called viruses cause infections. The common cold is a virus. Minocycline hydrochloride capsules USP, like other antibiotics, do not treat viruses.

Do not take minocycline hydrochloride capsules USP if you are allergic to minocycline or other tetracycline antibiotics.

Ask your doctor or pharmacist for a list of these medications if you are not sure. See the end of this leaflet for a complete list of ingredients in minocycline hydrochloride

Minocycline hydrochloride capsules USP are not recommended for pregnan women or children up to 8 years old because:

Minocycline hydrochloride capsules USP may permanently turn a baby's or child's teeth yellow-gray-brown during tooth development. Tooth development happens in the last half of pregnancy and birth to age 8 years.

Indegrading provides
 are pregnant or planning to become pregnant. Minocycline hydrochloride capsules USP may harm your unborn baby. Stop taking minocycline hydrochloride capsules USP and call your doctor if you become pregnant

are breast feeding. Minocycline passes into your milk and may harm your baby. You should decide whether to use minocycline hydrochloride capsules USP or breastfeed, but not both.

Tell your doctor about all the medicines you are taking including prescription and non prescription medications, vitamins, and herbal supplements. Minocycline hydrochloride capsules USP and other medicines may interact. Especially tell your doctor if you take:

· birth control pills. Minocycline hydrochloride capsules USP may make your

• a blood thinner medicine. The dose of your blood thinner may have to be

-a penicillin antibiotic medicine. Minocycline hydrochloride capsules USP and penicillins should not be used together.

 An acne medicine called isotretinoin (Accutane, Amnesteem, Claravis, Sotret) Antacids that contain aluminum, calcium, or magnesium, or iron-containing products.

What should I tell my doctor before starting minocycline hydrochloride capsules USP?

1. Minocycline hydrochloride capsules USP may harm an unborn baby

Tell your doctor about all of your medical conditions, including if you

have liver or kidney problems

hirth control nills less effective

• Migraine medicines called ergot alkaloids

while taking them

Who should not use minocycline hydrochloride cansules USP?

What are minocycline hydrochloride cansules IISP?